The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
 
Priyanka Sharma
Consulting or Advisory Role - AstraZeneca; Epic Sciences; Exact Sciences; Merck; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Cosmo Biosciences (I); Merck (Inst); Novartis (Inst)
 
Eve Rodler
No Relationships to Disclose
 
William E. Barlow
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Merck (Inst)
 
Julie Gralow
Consulting or Advisory Role - AstraZeneca; Genentech; Genomic Health; Immunomedics; Merck; Novartis; Pfizer; Puma Biotechnology; Sandoz
 
Shannon Leigh Huggins-Puhalla
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; Puma Biotechnology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Pfizer (Inst)
 
Carey K. Anders
Honoraria - Eisai; Genentech/Roche; IPSEN; Puma Biotechnology; Seagen
Consulting or Advisory Role - Eisai; Genentech/Roche; Ipsen; Puma Biotechnology; Seagen
Research Funding - G1 Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Puma Biotechnology (Inst); Seagen (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Jones and Bartlett; Up to Date.com
Travel, Accommodations, Expenses - Eisai
 
Lori J. Goldstein
Honoraria - Daiichi Sankyo; Genomic Health; Roche/Genentech; Teva
Consulting or Advisory Role - Aduro Biotech; Amgen; Eisai; Genentech; Genomic Health; Immunomedics; Merck; Mylan; Myriad Genetics; NanoString Technologies; Puma Biotechnology; Syndax
Research Funding - Genentech/Roche (Inst); Merck (Inst)
Other Relationship - Daiichi Sankyo
 
Ursa Abigail Brown-Glaberman
Consulting or Advisory Role - Biotheranostics; Eisai; Novartis; Syndax
Research Funding - Seagen (Inst)
 
Thu-Tam Huynh
No Relationships to Disclose
 
Christopher Scott Szyarto
No Relationships to Disclose
 
Andrew K. Godwin
Honoraria - Sinochips Kansas
Consulting or Advisory Role - NanoString Technologies; Personal Genome Diagnostics
Research Funding - BioFluidica (Inst)
Travel, Accommodations, Expenses - Personal Genome Diagnostics; West China Cooperative Network of Pharmacy
 
Harsh B Pathak
No Relationships to Disclose
 
Elizabeth M. Swisher
No Relationships to Disclose
 
Marc R Radke
No Relationships to Disclose
 
Kirsten M Timms
Employment - Myriad Genetics
Stock and Other Ownership Interests - Myriad Genetics
Patents, Royalties, Other Intellectual Property - Inventor on numerous patents
Travel, Accommodations, Expenses - Myriad Genetics
 
Danika L. Lew
No Relationships to Disclose
 
Jieling Miao
No Relationships to Disclose
 
Lajos Pusztai
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Athenex; Bristol-Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Genentech (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - NanoString Technologies
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Consulting or Advisory Role - Agendia; Cellworks; Cepheid; CVS Caremark; Epic Sciences; Freenome; Salutogenic Innovations
Research Funding - AstraZeneca (Inst); Lilly (Inst); Menarini Silicon Biosystems (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Menarini Silicon Biosystems
Other Relationship - Menarini
(OPTIONAL) Uncompensated Relationships - UpToDate
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - Agendia; Novartis; Peregrine Pharmaceuticals
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis